Found: 8
Select item for more details and to access through your institution.
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 24, p. 2808, doi. 10.3390/cells12242808
- By:
- Publication type:
- Article
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
- Published in:
- Rheumatology International, 2024, v. 44, n. 2, p. 249, doi. 10.1007/s00296-023-05455-7
- By:
- Publication type:
- Article
Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.
- Published in:
- Rheumatology International, 2021, v. 41, n. 10, p. 1833, doi. 10.1007/s00296-021-04887-3
- By:
- Publication type:
- Article
The relation of partners' illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patients' illness representation: A dyadic regulation process.
- Published in:
- Current Psychology, 2023, v. 42, n. 20, p. 16923, doi. 10.1007/s12144-022-02937-y
- By:
- Publication type:
- Article
Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors?
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 21, p. 6945, doi. 10.3390/jcm12216945
- By:
- Publication type:
- Article
Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Rituximab therapy in Greek patients with rheumatoid arthritis.
- Published in:
- Biologics: Targets & Therapy, 2008, v. 2, n. 4, p. 911
- By:
- Publication type:
- Article
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
- Published in:
- Arthritis Research & Therapy, 2022, v. 24, n. 1, p. 1, doi. 10.1186/s13075-022-02826-6
- By:
- Publication type:
- Article